Fluoroquinolones: Is Another FDA Safety Step Needed?
This article was originally published in The Pink Sheet Daily
Joint advisory committee meeting will discuss post-marketing safety data, including adverse events across organ systems.
You may also be interested in...
Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.
Advisory committee unsure how to describe fluoroquinolone-associated disability in labeling.
Overwhelming votes against existing labels for the antibiotics likely means sponsors and FDA have some safety planning to do.